Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice
Stabile LP, Rothstein ME, Keohavong P, Lenzner D, Land SR, Gaither-Davis AL, Kim KJ, Kaminski N, Siegfried JM. Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice. Cancers 2010, 2: 2153-2170. PMID: 21390244, PMCID: PMC3049550, DOI: 10.3390/cancers2042153.Peer-Reviewed Original ResearchHepatocyte growth factorLung cancerC-MetLung tumorigenesisAdditive anti-tumor effectsSmall molecule c-Met inhibitorsNon-small cell lung cancer cellsCell lung cancer cellsK-ras mutation rateHGF/c-MetLung cancer casesHuman hepatocyte growth factorAnti-tumor effectsLung cancer cellsEGFR inhibitor gefitinibSimilar downstream signalingC-Met inhibitorsAirway expressionSingle blockadeDual blockadeTumor numberClinical benefitTobacco carcinogensCancer casesLung tumors